Welcome to our dedicated page for SCOPUS BIOPHARMA news (Ticker: SCPS), a resource for investors and traders seeking the latest updates and insights on SCOPUS BIOPHARMA stock.
Scopus Biopharma Inc. (SCPS) is a biopharmaceutical company focused on developing novel therapeutic candidates to treat serious diseases with significant unmet medical needs. The company engages in the discovery, development, and commercialization of innovative medicines. Scopus Biopharma's core business involves leveraging proprietary technologies and collaborating with academic institutions to advance its product pipeline.
Scopus Biopharma has a diverse portfolio of drug candidates, including immuno-oncology treatments, antiviral therapies, and regenerative medicines. One of their leading projects is the development of a small molecule that targets certain genetic markers associated with various cancers, which has shown promising preclinical results.
The company has established strategic partnerships with leading research institutions and biotech firms to enhance its R&D capabilities and accelerate the clinical development of its therapeutics. Scopus Biopharma's financial health is bolstered by successful funding rounds and a strong commitment to maintaining a robust balance sheet.
Recent achievements include the initiation of early-stage clinical trials for their lead cancer treatment candidate and collaborations aimed at expanding their research into new therapeutic areas. These milestones signify the company's dedication to bringing groundbreaking treatments to market.
Investors and stakeholders can look forward to continuous updates on Scopus Biopharma's progress, as the company remains at the forefront of biopharmaceutical innovation. The ongoing commitment to addressing critical health challenges underscores the importance of Scopus Biopharma in the biotech landscape.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced an adjournment of its upcoming Annual Meeting originally set for October 8, 2021, due to pending claims from Dr. Morris C. Laster. The meeting will not proceed until at least 14 days after a decision or settlement between the parties. The record date for stockholders remains August 16, 2021. No business will be conducted during the adjourned meeting, but existing proxy votes can still be used. The company will keep stockholders updated and file additional proxy materials as needed.
Scopus BioPharma (Nasdaq: SCPS) has announced the launch of its wholly-owned subsidiary, Duet Therapeutics, focused on immuno-oncology. The company will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, featuring a presentation by Alan Horsager, Ph.D. The Duet Platform comprises three innovative CpG-STAT3 inhibitors, with DUET-01 in clinical trials for B-cell non-Hodgkin lymphoma. Future IND filings for DUET-02 are anticipated in Q4 2022, targeting genitourinary and head & neck cancers.
Scopus BioPharma (Nasdaq: SCPS) announced that Alan Horsager, Ph.D., CEO of Duet Therapeutics, will present key research at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society on September 29, 2021. He will discuss DUET-01, targeting B-cell lymphoma, and DUET-02 for solid tumors. The Duet Platform combines immunotherapy assets and consists of three unique CpG-STAT3 inhibitors. Current developments include Phase 1 trials for DUET-01 and upcoming IND filings for DUET-02 in late 2022, with trials anticipated to begin in early 2023.
Scopus BioPharma (Nasdaq: SCPS) announced the grant of a new patent by the China National Intellectual Property Administration for its CpG-STAT3 Antisense inhibitor, DUET-02. This patent enhances the company's position in China's rapidly growing biotech sector, which has seen a market value surge to approximately $180 billion as of May 2021. DUET-02 is poised for clinical trials in the U.S. for treating genitourinary and head & neck cancers in early 2023. The patent strengthens Scopus' global patent portfolio, which also includes pending applications in the EU, Canada, and Japan.
On September 20, 2021, Dr. Morris C. Laster announced he has filed preliminary proxy materials with the SEC for the 2021 Annual Meeting of Scopus BioPharma (SCPS) on October 8, 2021. Dr. Laster, holding 33.2% of outstanding shares, nominated candidates Mordechai Saar Hacham and Joshua Levine for election to the Board. He expressed concerns over corporate governance issues and allegations of misconduct involving board members affiliated with HCFP/Capital Partners, affecting shareholder interests.
Scopus BioPharma (Nasdaq: SCPS) announced the appointments of John Rossi, Ph.D., and Nagy Habib, Ch.M., F.R.C.S., to its Scientific Advisory Board at Duet Therapeutics, a wholly-owned subsidiary. Dr. Rossi is a leader in RNA interference and has co-founded several biotech firms, including Dicerna Pharmaceuticals. Professor Habib is a hepatobiliary surgeon known for pioneering RNA oligonucleotide trials in liver cancer. Their expertise will guide the development of three CpG-STAT3 inhibitors at Duet aimed at addressing serious diseases. This leadership change is anticipated to enhance the company's innovative therapeutic approaches.
Scopus BioPharma (Nasdaq: SCPS) has announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company will present the launch of its wholly-owned subsidiary, Duet Therapeutics, which focuses on immuno-oncology. Duet combines immunotherapy assets from Scopus and Olimmune, featuring the Duet Platform with three complementary CpG-STAT3 inhibitors: DUET-01 (RNA silencing), DUET-02 (antisense), and DUET-03 (DNA-binding inhibitor).
CEO Alan Horsager will present on-demand starting at 7 A.M. EST on September 13, 2021.
Scopus BioPharma (Nasdaq: SCPS) announced the appointment of Dr. Marcin Kortylewski as Senior Scientific Advisor to Duet Therapeutics, a wholly-owned subsidiary focusing on immunotherapy. Dr. Kortylewski, an authority in bi-functional oligonucleotide cancer therapeutics, will guide the development of three innovative CpG-STAT3 inhibitors within the newly formed Duet Platform. His expertise is expected to enhance the potential of these therapies. Additionally, he will chair discussions and present at the upcoming 14th Annual RNA Consortium Meeting, highlighting advancements in cancer immunotherapy.
Scopus BioPharma (Nasdaq: SCPS) announced that Alan Horsager, Ph.D., President and CEO of Duet Therapeutics, will present at the 14th Annual RNA Consortium Meeting on September 10, 2021. His presentation will focus on the Clinical Development of CpG-STAT3 Inhibitors, part of the Duet Platform, which includes innovative therapies for solid tumors and hematological malignancies. The platform integrates immunotherapy assets from Scopus and Olimmune, showcasing three distinct CpG-STAT3 inhibitors, aimed at addressing critical medical needs.
Scopus BioPharma (Nasdaq: SCPS) has launched Duet Therapeutics, a subsidiary that integrates the immunotherapy assets of Scopus and Olimmune, acquired in June 2021. This integration will enhance their portfolio of bi-functional cancer-targeting oligonucleotides aimed at inhibiting STAT3, a key immune checkpoint. The Duet platform includes three technologies: DUET-01 for B-cell non-Hodgkin lymphoma, DUET-02 targeting genitourinary and head & neck cancers, and DUET-03 focusing on protein degradation. The company anticipates filing two INDs in 2022 for DUET-02.
FAQ
What is the current stock price of SCOPUS BIOPHARMA (SCPS)?
What is the market cap of SCOPUS BIOPHARMA (SCPS)?
What does Scopus Biopharma Inc. do?
What are some of the company’s core products?
What are some recent achievements of Scopus Biopharma?
Who are Scopus Biopharma’s partners?
What is the financial condition of Scopus Biopharma?
What type of diseases does Scopus Biopharma target?
Why is Scopus Biopharma significant in the biotech landscape?
How does Scopus Biopharma advance its pipeline?
What is the company’s approach to research and development?
Where can I find updates on Scopus Biopharma’s progress?
